Product Description
Tolcapone is a medication used in the management and treatment of Parkinson disease. It is in the catechol-O-methyl transferase inhibitor class of drugs. This activity reviews the indications, action, and contraindications for tolcapone as a valuable agent in the management of Parkinson disease. (Sourced from: https://www.ncbi.nlm.nih.gov/books/NBK560593/)
Mechanisms of Action: COMT Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Austria | Belgium | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hungary | Iceland | Ireland | Italy | Latvia | Lithuania | Netherlands | New Zealand | Norway | Poland | Portugal | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Turkey | United Kingdom | United States | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|